Cerebral infarction is normally caused by thrombosis in chronic cardiogenic patients. However, it may be an acute appearance after surgery because of thrombus formation in dammaged vascular. The left upper lobectomy is the highest risk factor for cerebral infarction among anatomical lung resection. Here we report a 69-year-old patient who presented with left hemiparesis after left upper lung lobectomy on the fourth day. We strongly suspect that cerebral infarction is one of cardiopulmonary complications after anatomical lung resection in this case

Background: Systemic lupus erythematosus (SLE) is a chronic disease that causes systemic inflammation which affects multiple organs. There is no cure for SLE. Conventional treatment options include antimalarial drugs, corticosteroids, and immune suppressants, but a number of patients are resistant to treatment or suffer from severe side effects. Stem cell transplantation has been used to treat SLE for the past 2 decades. We describe the first Vietnamese patient with refractory SLE who received an autologous hematopoietic stem cell transplant. Case presentation: The patient is a woman who was diagnosed 12 years ago with systemic lupus erythematosus. She was administered corticosteroids and high-dose immunosuppressive medicines, but the condition was refractory, manifesting as severe headache, arthralgia, chronic anemia, severe Cushing's syndrome, and proteinuria. At admission, the SLEDAI score was 28 and proteinuria was 6.7g/l. She received cyclophosphamide and G-CSF for HSCT mobilization. Peripheral blood stem cells were collected and selected for CD34+ cells. Antithymocyte, cyclophosphamide, and rituximab were used in conditioning regimens. The patient was then administered a CD34+ autologous hematopoietic stem cell transfusion with a CD34+ dose of 7.93 x 106 cells/kg body weight, T and B lymphocyte purity of the graft exceeded 99.99%. Post-transplant course was favorable, the patient did not experience serious complications. Recovery of neutrophils on post-HSCT day +9 and platelet on day +12. Six months after stem cell transplantation, the patient's clinical symptoms significantly improved, the SLEDAI score dropped from 28 to 0, and the patient discontinued receiving immunosuppressive drugs. Conclusion: Autologous hematopoietic stem cell transplantation promises to be a new, effective therapeutic method that can be implemented more broadly in Vietnam for SLE patients.

Autologous hematopoietic stem cell transplantation therapy has been widely used in recent decades for the treatment of hematological diseases, cancer, and autoimmune diseases. In autoimmune diseases, self-activated T lymphocytes and B lymphocytes secreting antibodies against host antigens are considered to be central in the pathogenesis of the disease. Autologous stem cell products that eliminates these pathological cells could be a lifesaver for patients with autoimmune diseases who are resistant to conventional therapy, in order to restore a healthy immune system, achieve long-term remission and limited recurrence. The aims of this study was to complete and evaluate the results of the CD34 positive stem cells purification procedure from a myasthenia gravis patient’s mobilized peripheral blood stem cells, for the purpose of autologous hematopoietic stem cell transplantation for Myasthenia gravis as well as other autoimmune diseases in Vietnam. We have completed the purification procedure of CD34-positive stem cells from mobilized peripheral blood stem cells of patient with myasthenia gravis using CliniMACS system with results of removing 99.99% of T lymphocytes; 99.81% of B lymphocytes; 99.99% of NK cells, while CD34+ recovery performance was 64.05% with CD34+ cell survival rate of over 99%, no bacterial contamination, ensuring quality assurance of stem cell product for transplantation.